title: Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options.
authors.affiliation: Mellen Center for MS Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
authors.forename: Robert A
authors.initials: RA
authors.lastname: Bermel
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Cohen
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000284:Administration, Oral; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000927:Anticonvulsants / Q000008:administration & dosage; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use; D000077213:Lamotrigine; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000209:etiology / Q000235:genetics; D000069442:Natalizumab; D014227:Triazines / Q000008:administration & dosage
chemical_list: D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000927:Anticonvulsants; D007155:Immunologic Factors; D000069442:Natalizumab; D014227:Triazines; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000077213:Lamotrigine